kringle-pharmaCo., Ltd.

NEWS

notice

Oct 30, 2008 Notice

Kringle Pharma Achieved Permission to Conduct Phase 1 Clinical Studies on recombinant human HGF for the Treatment of ARF in US.

Kringle Pharma Achieved Permission to Conduct Phase 1 Clinical Studies on recombinant human HGF for the Treatment of ARF in US.